机构：[1]Division of Population Medicine, School of Medicine, Cardiff University, Wales, UK.[2]Evidence-Based Health Care Ltd, Edinburgh, UK.[3]Allergy Unit - Department of Pediatrics, University of Messina, Via Consolare Valeria - Gazzi, Messina, Italy.[4]Molecular Allergology and Immunomodulation-Department of Pediatric Pneumology and Immunology, Charité Medical University, Augustenburger Platz 1, Berlin, Germany.[5]The David Hide Asthma and Allergy Research Centre, St Mary's Hospital, Newport Isle of Wight, UK.[6]NIHR Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust and Faculty of Medicine, University of Southampton, Southampton, UK.[7]Department of Otorhinolaryngology, Head and Neck Surgery, Universitätsmedizin Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.[8]Center for Rhinology and Allergology, Wiesbaden, Germany.[9]Food Allergy Referral Centre Veneto Region, Department of Women and Child Health, Padua General University Hospital, Padua, Italy.[10]Hospital Quiron Bizkair, Bilbao, Spain.[11]National Heart and Lung Institute, Imperial College, London, UK.[12]Department of ENT, Eskisehir Osmangazi University Medical Faculty, Eskisehir, Turkey.[13]Section of Allergology, Department of Internal Medicine, Erasmus MC, Rotterdam, The Netherlands.[14]Hans Christian Andersen Children's Hospital, Odense University Hospital, Odense, Denmark.[15]Children's Center Bethel, EvKB, Bieledelf and Allergy Center, Buhr-University, Bochum, Germany.[16]Laboratory of Experimental Immunology, University Hospitals Leuven, Louvain, Belgium.[17]ALCAllergy Learning and Consulting, Copenhagen, Denmark.[18]University Medical Center, Utrecht, The Netherlands.[19]Hospital Medica Sur, Mexico City, Mexico.[20]Department of Otolaryngology-Head &[21] Neck Surgery, John Hopkins, Baltimore, MD USA.[21]Allergy and Clinical Immunology Unit, 2nd Department of Pediatrics, University of Athens, P&[23]A Kiriakou Children's Hospital, Athens, Greece.[22]Department of Allergology, Groningen Research Institute for Asthma and COPD (GRIAC), University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.[23]Department of Pediatrics, Nippon Medical School, Tokyo, Japan.[24]University of Milano, Milan, Italy.[25]Medical School, University of Cyprus, Nicosia, Cyprus.[26]The Royal National Throat, Nose and Ear Hospital, University College London, London, UK.[27]Netherlands Anafylaxis Network, Dordrecht, The Netherlands.[28]Department of Paediatrics, Respiratory and Allergic Disease Division, Medical University Graz, Graz, Austria.[29]Pharmaceutical Group of the European Union, Brussels, Belgium.[30]Guy's and St Thomas' NHS Foundation Trust, London, UK.[31]Charitie-Universitatsmedizin, Berlin, Germany.[32]Beijing Institute of Otolaryngology, Beijing, China.研究所耳鼻咽喉科研究所首都医科大学附属北京同仁医院首都医科大学附属同仁医院[33]Allergy and Respiratory Research Group, The University of Edinburgh, Edinburgh, UK.
The European Academy of Allergy and Clinical Immunology (EAACI) is developing Guidelines on Allergen Immunotherapy (AIT) for Allergic Rhinoconjunctivitis (ARC). To inform the development of recommendations, we sought to critically assess the systematic review evidence on the effectiveness, safety and cost-effectiveness of AIT for ARC.We undertook a systematic overview, which involved searching nine international biomedical databases from inception to October 31, 2015. Studies were independently screened by two reviewers against pre-defined eligibility criteria and critically appraised using the Critical Appraisal Skills Programme (CASP) Systematic Review Checklist for systematic reviews. Data were descriptively synthesized.Our searches yielded a total of 5932 potentially eligible studies, from which 17 systematic reviews met our inclusion criteria. Eight of these were judged to be of high, five moderate and three low quality. These reviews suggested that, in carefully selected patients, subcutaneous (SCIT) and sublingual (SLIT) immunotherapy resulted in significant reductions in symptom scores and medication requirements. Serious adverse outcomes were rare for both SCIT and SLIT. Two systematic reviews reported some evidence of potential cost savings associated with use of SCIT and SLIT.We found moderate-to-strong evidence that SCIT and SLIT can, in appropriately selected patients, reduce symptoms and medication requirements in patients with ARC with reassuring safety data. This evidence does however need to be interpreted with caution, particularly given the heterogeneity in the populations, allergens and protocols studied. There is a lack of data on the relative effectiveness, cost-effectiveness and safety of SCIT and SLIT. We are now systematically reviewing all the primary studies, including recent evidence that has not been incorporated into the published systematic reviews.
语种：
外文
PubmedID：
中科院(CAS)分区：
出版当年[2016]版：
无
最新[2025]版：
大类|2 区医学
小类|3 区过敏
第一作者：
第一作者机构：[1]Division of Population Medicine, School of Medicine, Cardiff University, Wales, UK.
通讯作者：
推荐引用方式(GB/T 7714)：
Nurmatov Ulugbek,Dhami Sangeeta,Arasi Stefania,et al.Allergen immunotherapy for allergic rhinoconjunctivitis: a systematic overview of systematic reviews.[J].Clinical and translational allergy.2017,7:24.doi:10.1186/s13601-017-0159-6.
APA：
Nurmatov Ulugbek,Dhami Sangeeta,Arasi Stefania,Roberts Graham,Pfaar Oliver...&Sheikh Aziz.(2017).Allergen immunotherapy for allergic rhinoconjunctivitis: a systematic overview of systematic reviews..Clinical and translational allergy,7,
MLA：
Nurmatov Ulugbek,et al."Allergen immunotherapy for allergic rhinoconjunctivitis: a systematic overview of systematic reviews.".Clinical and translational allergy 7.(2017):24
